3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
28
Neoplasm Metastasis
6
Recurrence
5
Breast Neoplasms
4
Stomach Neoplasms
3
Prostate Cancer Metastatic
3
Neoplastic Cells, Circulating
3
Carcinoma, Transitional Cell
3
Carcinoma, Non-Small-Cell Lung
3
Ovarian Neoplasms
2
Brain Neoplasms
2
Urinary Bladder Neoplasms
1
Testicular Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Prostatic Neoplasms, Castration-Resistant
1
Prostate Cancer, Hereditary, 7
1
Penile Neoplasms
1
Nonseminomatous germ cell tumor
1
Metastatic Castration-resistant Prostate Cancer, MCRPC
1
Metastatic Castration-resistant Prostate Cancer
1
Metastatic Breast Cancer With Intracranial Metastases
1
Lung Neoplasms
1
Liposarcoma
1
Hormone-Resistant Prostate Cancer
1
Hormone Refractory Prostate Cancer
1
Head and Neck Neoplasms
1
Glioblastoma
1
Esophageal Neoplasms
1
Diarrhea
1
Interventions
enzalutamide
3
testosterone 17 beta-cypionate
2
darolutamide
2
abiraterone
2
Docetaxel
2
Androgen Antagonists
2
sipuleucel-T
1
pamiparib
1
olaparib
1
lactitol
1
fluciclovine F-18
1
enfortumab vedotin
1
cabazitaxel
1
avelumab
1
Standard of Care
1
Selegiline
1
Prednisolone
1
Pluvicto
1
PSMA-617
1
Gonadotropin-Releasing Hormone
1
Bortezomib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Metastatic Castration-resistant Prostate Cancer
×
cabazitaxel
×
Clear all
NCT05762536
2024-06-27
DAROTAXEL
Erasmus Medical Center
Phase 2
Recruiting
245 enrolled